The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells
Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender R, Auernhammer C. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer 2011; 18:277-85.
21.03.2011
The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells
21.03.2011
Endocr Relat Cancer 2011; 18:277-85
Zitzmann Kathrin, de Toni Enrico, von Rüden Janina, Brand Stephan, Göke Burkhard, Laubender Rüdiger P, Auernhammer Christoph J
Weiter
